Fiduciary Family Office LLC Increases Position in IQVIA Holdings Inc. (NYSE:IQV)

Fiduciary Family Office LLC boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 165.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 5,666 shares of the medical research company's stock after acquiring an additional 3,530 shares during the quarter. Fiduciary Family Office LLC's holdings in IQVIA were worth $1,343,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of IQV. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA during the 2nd quarter worth approximately $27,000. Park Place Capital Corp purchased a new position in IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA in the second quarter valued at approximately $29,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft cut their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research report on Friday. Robert W. Baird decreased their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research report on Friday. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Morgan Stanley decreased their price target on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a report on Monday. Finally, Barclays cut their target price on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $259.13.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the firm's stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Price Performance

NYSE:IQV traded up $2.68 during trading hours on Tuesday, hitting $212.87. The company's stock had a trading volume of 1,125,580 shares, compared to its average volume of 1,092,316. The company has a market capitalization of $38.64 billion, a PE ratio of 27.54, a PEG ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 52-week low of $190.20 and a 52-week high of $261.73. The business's 50-day moving average is $233.55 and its two-hundred day moving average is $229.64. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.